Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 1

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 September 30,Nine Months Ended September 30, 2025202420252024Product revenue, net$207,638 $182,546 $559,282 $493,150 Operating expenses:Cost of sales4,596 2,867 10,432 7,926 Research and development68,846 59,336 190,052 176,587 Selling, general and administrative123,977 73,745 318,488 196,948 Total operating expenses197,419 135,948 518,972 381,461 Income from operations10,219 46,598 40,310 111,689 Interest and other income5,024 6,345 16,243 17,844 Income before income taxes15,243 52,943 56,553 129,533 Income tax benefit (expense)4,425 (5,730)18,811 (19,070)Net income19,668 47,213 75,364 110,463 Net income attributable to common stockholders19,359 46,690 74,267 109,344 Basic net income per common share$0.19 $0.45 $0.71 $1.06 Diluted net income per common share$0.16 $0.41 $0.62 $0.98 Weighted-average shares outstanding used in computing net income per common shareBasic103,545 103,371 103,919 103,094 Diluted119,439 113,723 119,981 111,571 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

CORCEPT THERAPEUTICS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands)Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024Net income$19,668 $47,213 $75,364 $110,463 Other comprehensive income (loss):Unrealized gain on available-for-sale investments, net of tax effect of $(116), $(256), $(270) and $(139), respectively370 951 1,084 432 Foreign currency translation (loss) gain(320)536 1,474 530 Total comprehensive